
A systematic review and meta-analysis comparing oral azithromycin and doxycycline in the treatment of Meibomian gland dysfunction (MGD) found that azithromycin was more effective in reducing the signs of MGD. The analysis, including 612 participants, revealed a statistically significant lower mean sign score with oral azithromycin compared to doxycycline. Although dioxycycline demonstrated a lower symptom score in one study, no clear differences in total scores between the two treatments were observed. Azithromycin also had a better safety profile, with fewer gastrointestinal side effects, including nausea, abdominal cramps, and diarrhea, compared to doxycycline. These findings suggest that azithromycin may be a preferable choice in managing MGD, though further studies are needed to confirm the optimal antibiotic treatment.
Like
Save
Share